Solvonis has secured £1m in funding from three shareholders (incl. the two largest) to accelerate development of its AI-supported CNS (central nervous system) drug discovery programme, which was formally initiated in June. The funding extends the company’s cash runway and will support discovery of potential new compounds targeting large, underserved neuropsychiatric conditions as well as its existing pre-clinical PTSD programme SVN-SDN-014. Whilst progress on SVN-001 remains the near-term value driver, the AI-supported programme will be key to Solvonis’ longer-term ambitions in establishing a CNS “hub-and-spoke” model. We will update our forecasts at the interims but importantly cash is now sufficient through to the end of 2026.
